Skip to main content
OpenTrials
Completed

NCT Number: NCT00647764

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Solid Tumor Malignancy Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Lymphatic Diseases Lymphoid Malignancy (Lymphoma and CLL) Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Pfizer Investigational Site

Bethesda, Maryland, 20892, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Solid tumors or lymphoid malignancies refractory to standard therapy
  • measurable disease
  • recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
  • no chemotherapy within 4 weeks of entering study
  • Age > 18 years
  • Karnofsy >= 60%
  • Life expectancy > 3 months
  • normal or adequate organ and marrow function

Exclusion criteria

  • receiving other investigational agents
  • brain metastases
  • uncontrolled medical illness
  • HIV+ receiving combination antiretroviral therapy
  • significant GI disease

Treatment and study plan

SNX-5422 Mesylate Hsp90 inhibitor

Drug

dose escalated, tablets twice a week; undetermined duration until disease progression

Primary outcomes

  1. MTD, safety and toxicity

    Time frame: continuous

Secondary outcomes

  1. pharmacokinetic profile of SNX-5422

    Time frame: first cycle

  2. tumor response measured by X-rays or scans

    Time frame: after every 2 cycles

Sponsors and collaborators

Lead sponsor

Esanex Inc.

Industry

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Apr 1, 2008
Registry last updated
May 17, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.